Get started
CRWV Weekly Options Outlook — June 3, 2025📈 CRWV Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bullish with Overbought Risk 🧠 Model Summary 🔹 Grok (xAI) Bias: Moderately Bullish Setup: +46% 5-day move, price > EMAs, RSI ~65, call OI stacked higher Trade: Buy $152.50C @ $7.75 → PT $9.69 (+25%), SL $6.20 Confidence: 70% 🔹 Claude (Anthropic) Bias: Moderately Bullish Setup: Strong momentum, MACD flattening, bullish flow, max pain at $128 Trade: Buy $155C @ $7.10 → PT $10.65 (+50%), SL $4.25 Confidence: 72% 🔹 Llama (Meta) Bias: Moderately Bullish (No Trade) Setup: Daily RSI >70, price overextended beyond Bollinger; MACD weakening Trade: No trade—premium too expensive, risk/reward not ideal 🔹 Gemini (Google) Bias: Moderately Bullish (No Trade) Setup: Parabolic move, minor MACD divergence, resistance near Trade: No trade—warns of short-term pullback risk 🔹 DeepSeek Bias: Moderately Bearish Setup: Daily RSI 72, MACD bearish divergence, low put OI Trade: Buy $140P @ $5.30 → PT $8.00, SL $4.30 Confidence: 65% ✅ Consensus Takeaways 📈 Price action is bullish — strong trend confirmed across models ⚠️ Overbought signals: RSI >70, Bollinger breakout, MACD divergence 🧲 Max pain at $128 = potential late-week gravity 💡 Only 2 models recommend entry (calls); 2 models abstain; 1 model (DeepSeek) favors puts 🎯 Recommended Trade 💡 Strategy: Bullish Naked Weekly Call 🔘 Ticker: CRWV 📈 Direction: CALL 🎯 Strike: $160 💵 Entry: $5.40 (ask) 🎯 Profit Target: $6.75 (+25%) 🛑 Stop Loss: $4.32 (−20%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 70% ⚠️ Key Risks to Watch 🔄 Overbought RSI + Bollinger extension = pullback risk 🧲 Max pain at $128 may drag price if momentum fades 💰 High IV = expensive premiums — reduce size or use tight SL ⌛ Theta decay accelerates Thursday–Friday — momentum must hold
NASDAQ:CRWVLong
by quantsignals
1
TSLA Weekly Options Outlook — June 3, 2025📉 TSLA Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bearish into June 6 Expiry 🧠 Model Breakdown 🔹 Grok (xAI) Bias: Bullish (Contrarian) Setup: 5-min RSI oversold (~23.5); daily momentum weakening. Trade: Buy $372.50C @ $0.88 → Bounce play Confidence: 65% 🔹 Claude (Anthropic) Bias: Bearish Setup: Daily/M5 MACD bearish; RSI oversold; max pain magnet at $340 Trade: Buy $340P @ ~$5.55 Confidence: 75% 🔹 Llama (Meta) Bias: Bearish Setup: Below EMAs; RSI oversold; mixed longer-term read Trade: Buy $342.50P @ $6.65 Confidence: 70% 🔹 Gemini (Google) Bias: Bearish Setup: Daily MACD bearish crossover; oversold short-term Trade: Buy $320P @ $1.06 Confidence: 65% 🔹 DeepSeek Bias: Bearish Setup: MACD and EMAs confirm bearish setup; near max pain Trade: Buy $340P @ $5.60 Confidence: 75% ✅ Consensus Summary 📉 4 of 5 models favor puts on TSLA 🧲 Max Pain at $340 is the dominant magnet 📉 Bearish MACD across timeframes; under EMAs 🔄 Short-term RSI is oversold — bounce risk acknowledged 📰 Mixed Tesla headlines & falling VIX offer minor support 🎯 Recommended Trade 💡 Strategy: Bearish Naked Weekly Put 🔘 Ticker: TSLA 📉 Direction: PUT 🎯 Strike: $340 💵 Entry: $5.60 🎯 Profit Target: $8.40 (+50%) 🛑 Stop Loss: $4.48 (−20%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 73% ⚠️ Key Risks to Watch 🔄 Bounce Risk: RSI oversold — snapback could occur 📰 Tesla news (Powerwall, China) could surprise to upside 🧲 Max pain at $340 may anchor price near entry ⌛ Weekly theta decay means early move is essential
NASDAQ:TSLAShort
by quantsignals
1
AAPL Weekly Options Outlook — June 3, 2025📈 AAPL Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bullish into June 6 Expiry 🧠 Model Summary 🔹 Grok (xAI) Bias: Moderately Bullish Setup: Price above EMAs, MACD divergence softening; resistance at $203.40 Trade: Buy $207.50C @ $0.67 → PT $1.00, SL if AAPL < $202 Confidence: 65% 🔹 Claude (Anthropic) Bias: Moderately Bullish Setup: Bullish reversal, rising EMAs, MACD improving Trade: Buy $207.50C @ $0.67 → PT $1.20–$1.80, SL $0.35 Confidence: 70% 🔹 Gemini (Google) Bias: Moderately Bullish Setup: Above EMAs, MACD histogram rising; resistance $203.46–$203.81 Trade: Buy $207.50C @ ~$0.65 → PT $0.97–$1.14, SL $0.32 Confidence: 65% 🔹 Llama (Meta) Bias: Moderately Bullish Setup: Above EMAs, MACD crossover building Trade: Buy $207.50C @ $0.67 → PT $0.80, SL $0.335 Confidence: 70% 🔹 DeepSeek Bias: Moderately Bearish Setup: MACD still negative; resistance at $203.81 Trade: Buy $200P @ $0.93 → PT $1.86, SL $0.46 Confidence: 65% ✅ Consensus Highlights 🔼 Bullish Momentum on short-term EMAs 📉 Max Pain at $200 could limit upside by Friday 📊 Strong liquidity on both $207.50C and $200P 🔁 Most models plan to exit midweek; only DeepSeek expects a breakdown 🎯 Recommended Trade Setup 💡 Strategy: Bullish Single-Leg Weekly Call 🔘 Ticker: AAPL 📈 Direction: CALL 🎯 Strike: $207.50 💵 Entry: $0.67 (ask) 🎯 Profit Target: $1.17 (+75%) 🛑 Stop Loss: $0.34 (−50%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 68% ⚠️ Risk Factors 📉 Max pain gravity could limit upside later in the week 🔼 Resistance zone at $207.50–$210 may stall momentum ⌛ Rapid theta decay — needs early move to profit 📰 Any negative macro or tech headlines could invalidate setup
NASDAQ:AAPLLong
by quantsignals
Sanofi takes a bold step by acquiring Blueprint MedicinesSanofi Makes Bold Move with $9.5 Billion Acquisition of Blueprint Medicines By Ion Jauregui – Analyst at ActivTrades French pharmaceutical giant Sanofi (EPA:SAN) has kicked off 2025 with a bold strategic move: the acquisition of U.S.-based biotech Blueprint Medicines (NASDAQ:BPMC) for up to $9.5 billion. The deal, expected to be the largest healthcare acquisition in Europe this year, includes an upfront payment of $129 per share, plus contingent value rights (CVRs) tied to the commercial success of BLU-808, a treatment for systemic mastocytosis. With this acquisition, Sanofi secures full control of Ayvakit, currently the only approved treatment for this rare disease, thereby strengthening its position in the lucrative rare diseases segment. Strong Financial Momentum in 2024 Sanofi’s latest annual results confirm the company’s solid trajectory. In 2024, the group generated €41.081 billion in revenue, representing a 11.3% increase at constant exchange rates. Adjusted net income reached €8.912 billion, up 4.1%, despite cost pressures in some segments. Flagship drug Dupixent, developed in partnership with Regeneron, brought in €13.072 billion, accounting for nearly a third of total group revenue. The vaccines segment also performed strongly, led by Beyfortus sales, with a growth of 13.5%. Favorable Market: Technical Analysis Sanofi shares have also been enjoying a positive trend. As of yesterday’s close, the stock was trading at €86.77, with a bullish pre-market and not far from its annual high of €106.20. From May to May, the stock gained as much as 47.43% year-over-year, reaching all-time highs. After the announcement of U.S. tariff policies, the stock corrected nearly 21%, but quickly recovered from a key support level at €82.51, now hovering near €87 with a positive outlook. The only technical concern lies in the bearish crossover of moving averages observed earlier this year. Should this acquisition reinforce Sanofi’s fundamentals, the resistance level around €93.70 may soon be breached and potentially become new support. Failure to do so, however, could see a short-term pullback toward €67.78. What’s clear is that the company is committed to maintaining its year-over-year growth trend and pushing for new record highs. Key technical levels: • Support: €79.80 (current point of control and mid-range zone) • Immediate resistance: €106.20 (52-week high) • RSI: 37.45 – signaling an oversold zone, possibly ready for recovery • Moving Averages: Showing a downward trend this quarter, requiring a shift to resume the bullish path From a fundamental perspective, the stock trades at an estimated P/E ratio of 12.7, which still offers value considering its earnings outlook and a solid dividend yield of 3.8%. Share Buyback and Clear Roadmap As part of its shareholder value strategy, Sanofi has launched an ambitious €5 billion share buyback program, equivalent to 4% of its capital. This move reflects management’s confidence in the company’s performance and comes amid strong cash flow generation. For 2025, Sanofi projects mid-to-high single-digit revenue growth and a low double-digit increase in adjusted net income. Conclusion: Innovation, Profitability, and Global Ambition The acquisition of Blueprint Medicines not only marks the largest healthcare deal in Europe this year, but also cements Sanofi’s strategic shift: focusing on innovative treatments, specialized markets, and global expansion. With a solid financial foundation, a technically strong stock, and a more focused product portfolio, Sanofi is emerging as a major player in the healthcare sector for 2025. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.
EURONEXT:SANLong
by ActivTrades
SWIGGY – Rounded Bottom Breakout with Volume SurgePattern: Rounded bottom Breakout level: ₹345 Current price: ₹355.55 (+6.71%) Volume: 24.64M (above 20-day average of 20.91M) RSI: 66.27 – strong bullish momentum Target: ₹409 (18 percent upside) Stop-loss: ₹324 Invalidation: Close below ₹340 with volume Context: A well-defined rounded base has broken out with strong follow-through. Volume exceeds the average, RSI confirms momentum, and the breakout candle shows no selling pressure. A bullish divergence in RSI had already signaled accumulation before price action confirmed it. Coverage initiation by Morgan Stanley aligns with, but does not drive, the technical breakout. Disclaimer: This analysis is intended for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading and investing in equities involve risk, including the risk of capital loss. The pattern recognition and breakout setup described here are based purely on technical chart analysis, without consideration of the company’s financial statements, earnings outlook, or valuation metrics. Market conditions can change rapidly, and price targets or stop-loss levels may not be respected under volatile scenarios. Always consult your financial advisor and conduct your own due diligence before making any investment decisions.
NSE:SWIGGYLong
by eggubonda
Canadian Natural resources is undervaluedUsing my simple method of technical analysis and fundamental calculation of the intrinsic value of a stock for which the range of intrinsic value of CNQ is between $35-$55. Assuming oil can make a reversal at this pivotal time in history for the world the stock looks very cheap. It also pays good dividends soon which was a bonus I bought some at $31 dollars for the market price. It looks like a great addition to make a nicely diversified portfolio.
NYSE:CNQLong
by Capitalist_Zach
TSLA long term game!See I think TSLA is a long term stock. With the innovation it is doing in energy, automobile, robotaxi(FSD), robotics... I believe it is in the front of technology for human kind. TSLA will inevitably impact each and every aspect of our day to day life. There is recent pullback potential to the Fib 0.5 of price $290, and that price is the resistance turned support. I believe it will retrace and people who were thinking to buy TSLA, might be a nice chance, just my simple opinion. A few bullish candle stick pattern in $282-$290 will support the long movement, I believe.
NASDAQ:TSLALong
by FinExcel
CARE - CUP WITH HANDLEPosition Update: May 16, 2025 Key factors: 1. Low-risk entry point. 2. Very clear bases with VCP characteristics. 3. A confirmed Stage 2 uptrend, indicating upward continuation. 4. The stock is outperforming, rising even as the broader market trends lower. 5. Displays strong relative strength against the market and peers. 6. Volume dries up suggests less supply coming to the market. 7. Many stocks start showing traction based on my own stock continuum. Considerations: While the breakout was not accompanied by a significant volume surge, this development is occurring within the early stages of what appears to be a new bull market cycle. This macro backdrop may provide additional support and follow-through potential. I’d like to see if it can hold up and follow through from here.
IDX:CARELong
by rifqonr
The 3 Step Rocket Booster StrategyOn this trade we are looking at the NASDAQ:AMZN trade.Now the special thing about this trade is that instead of focusing on the daily chart we are focusing on the weekly chart. You may be thinking “Why are we focusing on the weekly chart?” Well this is because you have to be ahead of the crowd nd see the coming trend. If you want to do your own trading strategy thats okay but if you want to learn more about the Rokcet booster strategy Then you need to follow these 3 steps • The price has to be above the 50 EMA • The price has to be above the 200 EMA • The price should gap up in an uptrend This is the rocket booster strategy In order to learn more Rocket boost this content Disclaimer:Trading is risky you will lose money so please use a simulation trading account before you trade with real money.Also learn Risk management and profit taking strategies.
NASDAQ:AMZNLong
by lubosi
KOTAKBANK Technical Analysis🏦 KOTAKBANK Technical Analysis (Daily Chart) – June 4, 2025 Current Price: ₹2,057.40 Change: +₹12.90 (+0.63%) 🔍 Chart Breakdown: Trendline Breakdown: Price has decisively broken below the ascending trendline, indicating weakness in bullish momentum. Bearish Structure: Lower highs and lower lows are forming — a classic sign of a downtrend resumption. Downside Target Zone: Primary Demand Zone: ₹1,840 – ₹1,880 🧭 Potential Scenarios: If current bearish pressure continues, price may slide toward the highlighted demand zone. A strong bullish rejection from the support zone could present a short-term reversal opportunity.
NSE:KOTAKBANKShort
by passionate_trader07
Beyond Bits: Is D-Wave Quantum the Unseen Power?D-Wave Quantum is rapidly solidifying its position as a transformative force in the burgeoning field of quantum computing. The company recently achieved a significant milestone with its Advantage2 system, demonstrating "beyond-classical computation." This breakthrough involved solving a complex simulation problem for magnetic materials in minutes, a task that would have required nearly a million years and the equivalent of the world's annual electricity consumption from the most powerful classical supercomputers. This distinct achievement, rooted in D-Wave's specialized quantum annealing approach, sets it apart from other industry players, including Google, which primarily focuses on gate-model quantum architectures. D-Wave's unique technological focus translates into a formidable commercial advantage. It stands as the sole provider of commercially available quantum computers, which excel at solving intricate optimization problems—a substantial segment of the overall quantum computing market. While competitors grapple with the long-term development of universal gate-model systems, D-Wave's annealing technology delivers immediate, practical applications. This strategic differentiation allows D-Wave to capture and expand its market share within an industry poised for exponential growth. Beyond its commercial prowess, D-Wave plays a critical role in national security. The company maintains deep ties with elite U.S. national security entities, notably through its backing by In-Q-Tel, the CIA's venture capital arm. Recent installations, such as the Advantage2 system at Davidson Technologies for defense applications, underscore D-Wave's strategic importance in addressing complex national security challenges. Despite its groundbreaking technology and strategic partnerships, D-Wave's stock experiences considerable volatility. This reflects both the speculative nature of a nascent, complex industry and potential market manipulations by investment houses with conflicting interests, highlighting the intricate dynamics surrounding disruptive technological advancements.
NYSE:QBTSLong
by UDIS_View
3
CE INFO SYSTEMS LTD S/RSupport and Resistance Levels: Support Levels: These are price points (green line/shade) where a downward trend may be halted due to a concentration of buying interest. Imagine them as a safety net where buyers step in, preventing further decline. Resistance Levels: Conversely, resistance levels (red line/shade) are where upward trends might stall due to increased selling interest. They act like a ceiling where sellers come in to push prices down. Breakouts: Bullish Breakout: When the price moves above resistance, it often indicates strong buying interest and the potential for a continued uptrend. Traders may view this as a signal to buy or hold. Bearish Breakout: When the price falls below support, it can signal strong selling interest and the potential for a continued downtrend. Traders might see this as a cue to sell or avoid buying. MA Ribbon (EMA 20, EMA 50, EMA 100, EMA 200) : Above EMA: If the stock price is above the EMA, it suggests a potential uptrend or bullish momentum. Below EMA: If the stock price is below the EMA, it indicates a potential downtrend or bearish momentum. Trendline: A trendline is a straight line drawn on a chart to represent the general direction of a data point set. Uptrend Line: Drawn by connecting the lows in an upward trend. Indicates that the price is moving higher over time. Acts as a support level, where prices tend to bounce upward. Downtrend Line: Drawn by connecting the highs in a downward trend. Indicates that the price is moving lower over time. It acts as a resistance level, where prices tend to drop. Disclaimer: I am not a SEBI registered. The information provided here is for learning purposes only and should not be interpreted as financial advice. Consider the broader market context and consult with a qualified financial advisor before making investment decisions.
NSE:MAPMYINDIA
by zenthosh